Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/39739
Title: Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Authors: 
Mesh: 
Issue Date: May-2017
Citation: Int. J. Clin. Pract..2017 May;(71)5:
Abstract: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β3 -adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.
PMID: 28419650
URI: https://hdl.handle.net/20.500.12530/39739
Rights: openAccess
Appears in Collections:Hospitales > H. U. Infanta Leonor > Artículos

Files in This Item:
File Description SizeFormat 
PMC5485167.pdf1.03 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.